Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $91.55, for a total transaction of $595,075.00. Following the transaction, the director now owns 274,725 shares of the company’s stock, valued at $25,151,073.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 89.44 on Monday. The firm has a 50 day moving average of $83.68 and a 200-day moving average of $89.69. The stock’s market capitalization is $22.18 billion. Vertex Pharmaceuticals Inc. has a 12 month low of $73.31 and a 12 month high of $134.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $413.78 million for the quarter, compared to analysts’ expectations of $423.53 million. Vertex Pharmaceuticals had a negative return on equity of 5.31% and a negative net margin of 13.45%. The business’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.13) earnings per share. Analysts forecast that Vertex Pharmaceuticals Inc. will post $0.78 earnings per share for the current year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Several large investors have recently modified their holdings of VRTX. Factory Mutual Insurance Co. increased its stake in Vertex Pharmaceuticals by 55.5% in the second quarter. Factory Mutual Insurance Co. now owns 255,000 shares of the pharmaceutical company’s stock worth $21,935,000 after buying an additional 91,000 shares during the last quarter. Creative Planning increased its stake in Vertex Pharmaceuticals by 2.0% in the second quarter. Creative Planning now owns 5,249 shares of the pharmaceutical company’s stock worth $451,000 after buying an additional 102 shares during the last quarter. Gateway Investment Advisers LLC increased its stake in Vertex Pharmaceuticals by 6.6% in the second quarter. Gateway Investment Advisers LLC now owns 172,581 shares of the pharmaceutical company’s stock worth $14,845,000 after buying an additional 10,684 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its stake in Vertex Pharmaceuticals by 1.5% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 238,987 shares of the pharmaceutical company’s stock worth $20,557,000 after buying an additional 3,634 shares during the last quarter. Finally, Exxonmobil Investment Management Inc. TX increased its stake in Vertex Pharmaceuticals by 6.7% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 64,027 shares of the pharmaceutical company’s stock worth $5,508,000 after buying an additional 4,037 shares during the last quarter. Institutional investors and hedge funds own 95.48% of the company’s stock.

VRTX has been the subject of a number of analyst reports. Jefferies Group reiterated a “buy” rating and issued a $107.00 price objective (up previously from $102.00) on shares of Vertex Pharmaceuticals in a research report on Sunday, July 31st. Morgan Stanley decreased their price objective on shares of Vertex Pharmaceuticals from $140.00 to $139.00 and set an “overweight” rating for the company in a research report on Thursday, July 28th. JMP Securities reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 16th. Leerink Swann set a $112.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, September 17th. Finally, RBC Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 12th. Sixteen investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $108.13.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.